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Abstract
Background: Major infectious disease outbreaks are a constant threat to human health. Clinical research responses
to outbreaks generate evidence to improve outcomes and outbreak control. Experiences from previous epidemics
have identified multiple challenges to undertaking timely clinical research responses. This scoping review is a
systematic appraisal of political, economic, administrative, regulatory, logistical, ethical and social (PEARLES)
challenges to clinical research responses to emergency epidemics and solutions identified to address these.
Methods: A scoping review. We searched six databases (MEDLINE, Embase, Global Health, PsycINFO, Scopus and
Epistemonikos) for articles published from 2008 to July 2018. We included publications reporting PEARLES
challenges to clinical research responses to emerging epidemics and pandemics and solutions identified to address
these. Two reviewers screened articles for inclusion, extracted and analysed the data.
Results: Of 2678 articles screened, 76 were included. Most presented data relating to the 2014–2016 Ebola virus
outbreak or the H1N1 outbreak in 2009. The articles related to clinical research responses in Africa (n = 37), Europe
(n = 8), North America (n = 5), Latin America and the Caribbean (n = 3) and Asia (n = 1) and/or globally (n = 22). A
wide range of solutions to PEARLES challenges was presented, including a need to strengthen global collaborations
and coordination at all levels and develop pre-approved protocols and equitable frameworks, protocols and
standards for emergencies. Clinical trial networks and expedited funding and approvals were some solutions
implemented. National ownership and community engagement from the outset were a key enabler for delivery.
Despite the wide range of recommended solutions, none had been formally evaluated.
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Conclusions: To strengthen global preparedness and response to the COVID-19 pandemic and future epidemics, identified
solutions for rapid clinical research deployment, delivery, and dissemination must be implemented. Improvements are
urgently needed to strengthen collaborations, funding mechanisms, global and national research capacity and capability,
targeting regions vulnerable to epidemics and pandemics. Solutions need to be flexible to allow timely adaptations to
context, and research led by governments of affected regions. Research communities globally need to evaluate their
activities and incorporate lessons learnt to refine and rehearse collaborative outbreak response plans in between epidemics.
Keywords: Challenges, Barriers, Solutions, Facilitators, Clinical research, Emerging infectious diseases, Epidemic, Pandemic,
Preparedness
Background
Clinical research forms the basis for evidence-based clinical
management of patients and can contribute to effective
outbreak control. Although activities have improved col-
lective preparedness to respond to public health emergen-
cies [1, 2], experiences from previous outbreaks have
highlighted many ongoing challenges for clinical research
responses to epidemics [3, 4]. Some of these stem from the
inherently unpredictable nature of emerging infections. Epi-
demics occur intermittently across geopolitical and cultural
boundaries. Some can be forecast, and others emerge unex-
pectedly and disproportionally affect resource-poor settings
with fragile healthcare systems and infrastructure, adding
additional challenges to responses [5]. Previous epidemics
have generated important information that has helped in-
form preparedness and response; however, it has also
highlighted systemic challenges to our global capability to
address important clinical research questions in these envi-
ronments [1]. Clinical research takes time to plan, conduct
and disseminate, a luxury that is rarely available during an
outbreak. Ethical and regulatory frameworks designed for
non-acute epidemics are not necessarily fit for the purpose
of acute epidemic research [6, 7]. Conducting research
under emergency conditions requires agility, intense activ-
ity, flexibility and adaptability to context [3, 4].
The aim of this scoping review is to identify how chal-
lenges to delivering essential clinical research during acute
epidemics and pandemics have been approached, in order
to inform strategies to strengthen our collective clinical
research preparedness to emerging epidemics [8]. This is,
to our knowledge, the first systematic scoping review of
solutions to political, economic, administrative, regulatory,
logistic, ethical and social (PEARLES) challenges to the
design, delivery and implementation of clinical research
during emerging epidemics and pandemics.
Methods
Drawing on PRISMA extension for scoping review
guidelines [9], we developed a scoping review protocol
in collaboration with researchers with experience in epi-
demic outbreak research and systematic evidence review
methodologies.
Inclusion criteria
We included published, peer-reviewed quantitative and
qualitative studies describing PEARLES challenges and
solutions to clinical research responses to epidemics or
pandemics identified during previous outbreak responses
or through research involving health system stake-
holders. We did not exclude reports based on study ade-
sign. We included editorials and other ‘opinion’ articles
when these were based on experiences derived from
clinical research responses to emerging epidemics or
pandemics. Conference abstracts were included as an
important source of data not yet published in full [10].
We excluded studies presenting findings only relating to
public health responses and not to clinical research.
Studies presenting study outcomes without a reflection
on challenges and/or solutions were excluded.
Search and retrieval of studies
The search strategy (Additional file 1) and terms were
developed collaboratively with an information specialist
who systematically searched six databases (Ovid MED-
LINE, Ovid Embase, Global Health, Ovid PsycINFO,
Scopus, Epistemonikos) for publications in English from
2008 to July 2018, to include up-to-date information
relevant to clinical research responses today. The limits
were set to capture recent, relevant clinical research re-
sponses to Public Health Emergencies of International
Concern (PHEIC), where a clinical research response is
vital to forward knowledge into risk factors and optimal
clinical care to improve patient outcomes and outbreak
control. The search terms were piloted by an informa-
tion specialist and two reviewers. To ensure the search
results were relevant and appropriate, after a review of
the pilot search, restrictions were implemented using
Boolean operators, before the strategy was finalised [9,
11, 12]. The search strategy was adapted for the Ovid
databases to include the relevant thesaurus terms, in
addition to searching the title or abstract fields (Table 1).
Two reviewers independently screened the title and ab-
stracts of the retrieved articles. If either of the reviewers
considered a study potentially eligible, the full-text
article was assessed independently for inclusion by two
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reviewers. Disagreements were resolved by a third re-
viewer. References were checked for additional poten-
tially eligible studies.
Data synthesis
One reviewer extracted data from the included studies
using standardised forms including information on (1)
study characteristics and setting, (2) participants, (3)
intervention, (4) type of outcome measures and (5)
PEARLES challenges and solutions. A second reviewer
checked the extracted data. At the first analysis stage, we
coded challenges and solutions according to the
PEARLES categories. This showed that although the
PEARLES categories were useful for the initial categor-
isation, there were overlap and interdependencies identi-
fied between these categories, especially between
political and economic factors and regulatory, logistic
and administrative factors and between ethical and social
factors. Thus, at the second stage of the analysis, two re-
viewers identified the sub-themes and actions that
emerged under these categories. A risk of bias assess-
ment was not carried out since none of the studies for-
mally evaluated the solutions identified during an
epidemic or pandemic. Most of the studies presented
challenges encountered while delivering clinical research
responses during emerging epidemics and solutions im-
plemented reactively, or solutions identified to address
these, without formal evaluation. Lower evidence arti-
cles, including opinion pieces, were included to enable
capturing the breadth and width of experiences from dif-
ferent settings, to give a voice to research teams deliver-
ing clinical research responses in difficult circumstances.
Studies covering PEARLES challenges and solutions
identified are summarised in the following sections
under the interdependent themes that emerged.
Results
Of the 2673 articles identified through database search-
ing, 234 full-text records were screened for inclusion, 71
of these met the inclusion criteria. Five additional arti-
cles were identified from references (Fig. 1).
Characteristics of included studies
The study designs of the 76 articles included were sys-
tematic review (n = 1), narrative reviews (n = 19),
randomised controlled trials (n = 7), other randomised
trials (n = 8; of which seven were stepped-wedge trials),
case-control study (n = 1), cohort studies (n = 3), cross-
sectional study (n = 1), time-in-motion study (n = 1),
qualitative studies (n = 15) and editorial, comments or
other ‘opinion’ pieces (n = 20) (Additional file 2). Most
articles presented challenges and solutions identified
during the Ebola virus epidemic in 2014 to 2016 and/or
during the H1N1 pandemic in 2009. Some articles fo-
cused on more than one type of outbreak (Table 2). The
studies which used an experimental design (e.g. RCTs)
were reporting solutions implemented to deliver the
intervention. Most articles related to clinical research re-
sponses set in lower-middle-income countries (LMICs)
in Africa (n = 37), Latin America and the Caribbean (n =
3) and Asia (n = 1). Thirteen articles related to research
responses in higher-income countries (HICs), and 22 ar-
ticles focused on a global perspective. Most articles ad-
dressed more than one PEARLES domains (Fig. 2).
Challenges and solutions
There were many solutions identified to address the
multiple challenges encountered. These are presented as
a narrative summary with illustrative examples from
some of the more complex studies. Key actions that
emerged are presented in Table 3. Many of these are
cross-cutting across domains (Fig. 3).
Political and economic solutions identified (Table 4)
Political impediments to global collaborative networking
and a lack of global coordination of funding and efforts
were the key challenges encountered [1, 15, 20, 21, 27,
33, 42]. Delays in mobilising funding [15, 27, 36, 37],
with approval sometimes taking longer than the out-
break duration, was a challenge during the H1N1 pan-
demic in HICs [15, 37] and again during the Ebola
outbreak in LMICs [36].
Strengthen collaboration and coordination
A cross-cutting theme identified was the need to
strengthen collaboration and coordination between orga-
nisations involved in outbreak response at all levels [3, 7,
13–37, 81]. Effective partnerships between countries and
international organisations, such as public health, clinical
research organisations, non-governmental organisations
(NGOs), pharmaceutical companies and regulatory agen-
cies, were described as instrumental for success [3, 14,
16, 19]. International research collaborations should be
tied to capacity building and be genuinely collaborative
[22], with local stakeholders engaged from inception [1,
3, 13, 16–19, 22, 26, 29, 31, 32, 36, 38, 40, 44, 50, 51].
Support from national governments and local communi-
ties was a key enabler [16, 17, 23, 32, 36]. Continuous
dialogue, led by governments of affected nations [16,
Table 1 The search strategy for Scopus and Epistemonikos
(zika* OR zikv* OR ebola* OR “middle east respiratory syndrome*” OR
“MERS-CoV” OR h7n9 OR h1n1 OR h5n1 OR nipah OR cholera* OR “yellow
fever” OR influenza OR ((outbreak* OR pandemic* OR epidemic*) AND
(“infectious disease*” OR “communicable disease*”))) AND (research OR
“clinical trial*” OR “vaccin* trial*”) AND (politic* OR economic* OR
administrat* OR regulat* OR logistic* OR ethic* OR social* OR cultur* OR
behavior* OR behaviour*) AND (barrier* OR bottleneck* OR delay* OR “time
delay*” OR expedite* OR solution* OR facilitate*).
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Fig. 1 PRISMA diagram
Table 2 Study setting and type of outbreaks. Several of the articles focused on a global perspective covered more than one type of
outbreak
Outbreak setting Ebola and other VHFs, n Arboviruses, n CNS infections, n ARI^, n Epidemics*, n Total, n (%)
Africa 35 – 1 – 1 37 (44)
Asia – – – 1 – 1 (1)
Europe 1 – – 7 – 8 (9)
Latin America and the Caribbean – 2 – – 1 3 (4)
North America – – – 5 – 5 (6)
Global perspective 13 2 – 6 9 30 (36)
Total, n (%) 49 (58) 4 (5) 1 (1) 19 (23) 11 (13) 84 (100)
VHF viral haemorrhagic fevers, Arboviruses arthropod-borne viruses, CNS central nervous system, ARI acute respiratory infections
*Non-specified emergency epidemics
^Includes articles focused on influenza, severe acute respiratory infections and pandemics
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17], was identified as a facilitator for ensuring politically
acceptable prioritisation and resource allocation [36].
This was illustrated by Doe-Anderson et al., where the
implementation of a vaccine RCT during an Ebola out-
break was attributed to decisive action by the national
government and an effective partnership between the
USA and Liberia, with strong leadership from both na-
tions [16]. By employing and training local doctors and
scientists and renovation of existing sites for use in the
trial, the study also strengthened the research capacity
for future trials [16].
Establish dedicated funding sources and accelerated
funding systems
There were many calls for dedicated funding for
emergency research [1, 15, 19, 26, 27, 32, 35, 37],
with financial mechanisms for rapid release of funds
[1, 15, 20, 21, 26, 27, 33, 42]. Maintaining political
awareness of the threat of infectious diseases to global
health security (GHS) [35, 63] and an integrated ap-
proach to research was recommended to help marshal
resources [1, 38]. A coalition of international stake-
holders that would provide a global financing facility
was suggested, to bring together funds to accelerate
and prioritise research and development (R&D) [26,
27] and support R&D for communicable diseases
neglected by the commercial market [13]. An example
from the UK showed that through an emergency pol-
icy activation that allowed expedited funding, approvals
and the redeployment of research staff, it was possible to
launch a national, multi-site clinical trial within 12 weeks
during the 2009 H1N1 pandemic [41, 53].
Invest in health systems and infrastructure in epidemic-
prone regions
Limited healthcare systems [3, 29, 32, 39] and support-
ing infrastructure [1–3, 17, 29, 32] and overwhelmed
healthcare facilities [31] brought about specific hurdles
for delivery of research in LMICs. Investments to
strengthen health systems and supporting infrastructure,
targeting regions vulnerable to epidemics and pandemics,
would facilitate effective responses [1, 2, 13, 29, 36]. Re-
searchers delivering an Ebola vaccine RCT in Sierra Leone
illustrated reactive solutions implemented to overcome lo-
gistic challenges. To enable recruitment of 8000 health-
care workers, they had to first renovate enrolment sites,
laboratories and cold chain facilities and build study facil-
ities and laboratories. Moreover, import freezer equipment
and instal satellite-routed internet [29, 42, 43].
Administrative, regulatory and logistic solutions identified
(Table 4)
Administrative and regulatory procedures and limited
access to staff with research training were persistent
challenges in LMICs and HICs [2, 3, 22, 29, 37, 43, 49,
50, 52]. Medical evacuation insurance requirements [42]
and delays in recruiting international staff [38] posed
additional challenges in LMICs. This can pose a risk of
over-reliance on unpaid staff doing research [22, 29] on
top of normal duties, with potential risk to routine patient
Fig. 2 Type of outbreak and PEARLES domains addressed. ^Articles focused on influenza, severe acute respiratory infections and pandemics;
*Non-specified emergency epidemics. VHF, viral haemorrhagic fevers; Arboviruses, arthropod-borne viruses; CNS, central nervous system; ARI,
acute respiratory infections
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care [72]. Multiple ethics committees, bureaucratic pro-
cesses and inconsistency between required documentation
were additional hurdles in LMICs and HICs [6, 15, 18, 40,
45, 46, 49, 50, 78], together with staff [42] and trial insur-
ance [69] cover. The longest delays were often experi-
enced in gaining site [48] and/or data sharing agreements,
as documented in a time-in-motion study by Rishu et al.
(Table 5) [15]. The infrastructure, staff time and an agreed
standard required for dissemination of data were also
often absent during times of crisis [2, 24, 35, 52] and were
further compounded by long delays in institutions
establishing data sharing agreements [15]. Some attributed
a competitive research culture and a fear of losing power
[22, 34] to a reluctance to share data [22, 34, 52, 73].
Develop research capacity
The data shows a need to strengthen research capacity
[1–3, 13, 29, 36] and invest in training for staff across
the board [1, 15, 40, 42, 45, 48] particularly in high-
risk regions. Primed clinical research networks glo-
bally [6, 24, 31, 37, 48] and a pool of researchers and
experts that can be redeployed were recommended [1,
Table 3 Key actions identified
Domain Key actions identified
Political and economic challenges Establish effective, coordinated, equitable collaborations between international and national
organisations involved in public health emergencies at all levels [1, 3, 7, 13–40]
Establish dedicated funding and coordinated, accelerated funding mechanisms
[1, 13, 15, 19–22, 24, 26, 27, 31–35, 37–39, 41]
Invest in health systems and infrastructure strengthening, targeting epidemic-prone
regions [1–3, 13, 17, 29, 31, 32, 36, 42–44]
Invest in sustainable clinical research centres and research training
[1, 3, 5, 6, 15–17, 20, 22, 29, 31, 33, 38, 44–48]
Incentivise clinical research response networks [1, 6, 15, 20, 22, 24, 31, 33, 37, 38, 41, 45, 48, 49]
Engage stakeholders in affected countries from inception
[1, 3, 13, 16–19, 22, 26, 29, 31, 32, 36, 38, 40, 44, 50, 51]
Administrative, regulatory and logistic challenges Develop human resource and research capacity
[1, 3–6, 13, 15–17, 20, 22, 29, 31, 33, 36, 38–40, 42–46, 48, 50, 52]
Train researchers, clinicians and other stakeholders for rapid deployment [1, 36, 38, 41, 53]
Develop international and national research, administrative and logistics support
platforms [1, 3, 4, 18, 20, 29, 32, 42, 43, 45, 47, 50–52, 54–56] with funded coordinating
mechanisms [39]
Agree R&D frameworks and standards for emergencies
[2, 5–7, 13, 14, 18, 19, 21, 22, 24, 26, 27, 35, 37, 39–41, 51, 52, 54, 57–60] include
national stakeholders [26, 38] and systems for evaluating the impact, regular
reviews and updating [19]
Develop pre-designed and pre-approved study protocols and associated tools for
different scenarios [1, 3, 4, 13, 15, 17, 20, 29, 34, 37, 41, 46, 48, 50, 51, 55, 56, 61–63]
Establish accelerated pathways for regulatory and ethical joint approvals
[1, 2, 6, 7, 13, 18, 20, 21, 32, 34, 37, 40, 41, 45, 49, 51, 53, 56, 64–66]
Set up pre-approved site agreements [4, 15, 38, 45, 46, 48, 61]
Establish international data and sample sharing agreements and templates
[7, 13, 18, 20, 22, 24, 25, 27, 28, 35, 44, 48, 52, 57, 58, 62, 67, 68]
Establish coordinated, effective internal and external stakeholder communication
and communication plans [3, 5, 14, 16, 18, 20, 23, 25, 29, 32, 34, 42, 46, 58, 65, 69–72]
Ethical emergency publication agreements with focus on timely, open data
sharing [2, 22, 38, 52, 68, 73]
Ethical and social challenges Explore and trial less complex consent models during emergencies
[2, 6, 15, 25, 32, 37, 44, 46, 48, 51, 69, 70, 74]
Develop frameworks for ethical and scientifically robust study designs for various
epidemic and pandemic scenarios [6, 13, 14, 17–19, 22, 27, 34, 36, 40, 42, 48, 51, 60, 61, 66, 75–77]
Develop international guidelines on ethical standards and conduct for emergencies,
including inclusion of vulnerable groups [5, 18, 21, 22, 27, 40, 44, 50, 51, 59, 60, 62, 69, 77, 78],
and equitable access to care and compensation [44, 59, 77, 79]
Engage and empower communities and stakeholder from the outset
[1, 3, 5, 14, 16, 17, 19, 20, 23, 26, 29, 32, 36, 39, 40, 42, 44, 50, 51, 54, 69, 71, 72, 79, 80]
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6, 41, 53]. The Platform for European Preparedness
Against (Re-) emerging Epidemics was cited as an ex-
ample of a clinical research network set-up to re-
spond at the outset of an epidemic [20].
Frameworks and standards
Internationally agreed frameworks for emergency re-
search to facilitate coordination, focus investments, and
to guide implementation of responses are needed. These
should identify emerging threats and develop roadmaps
to focus R&D investments [19], as well as ethical, regula-
tory and operational standards for conducting emer-
gency research [1, 7, 13, 19, 27, 35]. The World Health
Organization’s (WHO) R&D Blueprint was cited as an
example that aims to guide research efforts and set stan-
dards for high-priority pathogens [82].
Pre-approval and expedited, emergency protocols and
frameworks
Pre-approved, pre-positioned study protocols was a key so-
lution recommended to reduce set-up delays [1, 4, 13, 15,
20, 34, 37, 41, 46, 48, 50, 51, 56, 61–63]. These can be stra-
tegically developed for a range of syndromes and settings.
An international agreement on a financial mechanism to
manage clinical trial liability [32] and coverage provided by
affected countries [32] was suggested to address delays in
gaining insurance cover for all at-risk populations. An art-
icle by Lim et al. presented a trial in ‘hibernation’, with full
regulatory approvals in place set up in the UK ready to be
activated during a future pandemic [46]. Since not all even-
tualities can be predicted, there is also a need for expedited
approval processes for emergencies [1, 2, 6, 7, 13, 18, 32,
34, 41, 45, 53, 54, 56, 64]. There were a couple of examples
of expedited approvals (Table 6). A study by Annane et al.
concluded that parallel rather than sequential scientific, fi-
nancial, regulatory and ethics approval, and preparation of
study drugs by local pharmacists would have enabled a
multi-centre RCT of corticosteroids in ICU patients with
H1N1 influenza pneumonia in France to start 1month
earlier, before the peak ‘flu’ wave [6]. Pollard et al. noted
that despite expedited processes, the bureaucratic burden
was undiminished [53]. Expedited reviews need to be bal-
anced against risk for patients [56]. One article found that
double ethical review improved the quality of an Ebola
protocol and led to better protection of patients due to the
complementarity of the reviews [67]. Ethics commit-
tee staff with experience from epidemic research and
joint research ethics committees (RECs) with repre-
sentatives from all affected countries was recom-
mended to facilitate approvals [1, 2, 18, 45] and to
protect patient safety [2]. RECs should ensure that proto-
cols are consistent with community values [50], are collab-
orative and include capacity building [20, 22].
Dissemination
Keeping stakeholders informed of the study progress
was cited as a facilitator for engagement and delivery
and to prevent misinformation [5, 21, 29, 33]. However,
interim data sharing needs to be managed carefully to
reduce the risk of misinterpretations [69]. International
agencies, such as WHO, are advised to provide a plat-
form for harmonised data sharing [2, 13, 24, 27, 52] and
support capacity for data recording in LMICs. In order
to encourage data sharing, study approval and funding
may be made on the premise of data sharing, and inter-
national agreements include guidance on data sharing
between sponsors and host countries [52]. To control
data sharing, mechanisms need to be in place to ensure
that intellectual property, clinical governance and par-
ticipant confidentiality are maintained [13, 69]. To over-
come issues around traditional publication processes,
scientific journals should review policies to improve
Fig. 3 Key cross-cutting actions recommended
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Table 4 Solutions to PEARLES challenges encountered
Political and economic solutions identified Challenges encountered
Strengthen global collaborations and coalitions
-Ensure global political awareness of infectious disease threats.
-Strengthen collaborations between international organisations,
national leaders, public, private and local stakeholders.
-WHO to set out overarching research governance framework for
research in outbreaks.
-Integrate research in international outbreak response.
-Ensure interventions are supported by all stakeholders, including
national and local stakeholders.
-Close collaboration between local and international researchers from
research inception, tied to capacity building and be genuinely
collaborative.
-Research led by national teams.
-Invest in national public health research institutes globally, targeting
epidemic-prone regions.
Geopolitical
-Ineffective global coordination and collaboration.
-Research not integrated into national outbreak response.
-Establishing outbreak as international concern may depend on the
ability of LMICs to raise international interest.
-Lack of compliance with WHO core capacities to detect, assess,
report and respond.
-Need for political approval.
-Political unrest.
-Research priorities dictated by funding bodies.
-Lack of communication and engagement between stakeholders.
Funding
-Establish dedicated funding sources in inter-epidemic times.
-Establish international agreements on financial mechanisms for rapid
release of funding and for addressing clinical trial liability coverage.
-National governments to strengthen investments in preparedness
and response.
-Coordinate funding to ensure it is rapid and sufficient by using
international coalitions and economies of scale.
-Ensure sufficient, specific and flexible funding for research staff to
avoid healthcare opportunity costs.
-Explore industry funding to complement public funding.
-Provide appropriate compensation for participation in research.
Funding
-Insufficient funding resources.
-Delays in identifying funding.
-Weak funding mechanism and implementation for research in
emergencies and neglected and tropical disease.
-Funding not mobilisable at sufficient pace.
-Limited national health budgets dedicated to research response
efforts.
-Opportunity costs and competing interests.
-Over-reliance on unpaid staff doing research in addition to normal
duties, with risk to care, staff and research.
Health systems and infrastructure
-Strengthen health systems and research capacity.
-Strengthen supporting infrastructure, targeting regions vulnerable to
epidemics.
-Expand critical care resources.
-Develop clinical research facilities in predicted ‘hot spot’ regions.
Health systems and infrastructure
-Limited healthcare systems.
-Limited supporting infrastructure, electricity and water supply and
technical resources.
-Lack of national health research institutes.
-Competing interests of resources.
Administrative, regulatory and logistic solutions identified Challenges encountered
Human resources and research capacity
-Ensure capacity to respond to outbreaks across departments,
particularly in predictable epidemic-prone regions.
-Ensure sufficient support for ethics review boards.
-Identify and utilise existing skills and talents, re-deploy existing re-
search staff.
-Fund dedicated study teams to avoid additional burden on other
staff.
-Ensure adequate, sustained research training for staff, particularly
during stable periods.
-Establish clinical research networks that are incentivised and
prepared to respond to outbreaks and politically supported.
-Form research response teams, with dedicated research coordinators.
-Recruit additional staff from outside of the epidemic area to reduce
strain.
-Set up mobile research teams to reach large areas.
-Improve staff perception of research as a core role of healthcare
professionals.
Human resources and research capacity
-Limited number of staff.
-Risk of already scarce staff becoming overwhelmed and additional
burden of research activities across services.
-Training of staff in research not seen as a priority.
-Lack of research coordinators.
-Increased workload from study protocol risk negatively affecting
patient care.
-Difficulties in deploying staff internationally sufficiently rapidly in
the context of an outbreak.
Communication
-Establish direct stakeholder communication channels.
-Develop harmonised, coordinated communication activities with
shared oversight structures and joint management.
-Establish detailed communication and dissemination plans and
templates.
-Provide continuous updates on research activity to stakeholders as
appropriate through a variety of channels.
-Set up ‘pandemic champions’ to establish links with sites, to facilitate
coordination and to raise awareness.
Communication
-Data stored in countries other than that affected, disempowers the
national team.
-LMICs unable to access trial results after the study is completed.
-Challenges for LMICs to gain international interest from study
results.
-Challenging to control the interpretation of research output by the
media and political leaders.
Frameworks
-Establish a normative framework for research and development.
Frameworks
-Lengthy process of planning, formalising and gaining approval of
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Table 4 Solutions to PEARLES challenges encountered (Continued)
-Create frameworks and governance charts for clear decision-making
procedures, standard operational procedures and administrative
infrastructures.
-Prioritise research questions, pre-design study protocols and training
materials in advance, ready to be deployed.
study protocol.
-Lack of integrated standards for data collection and infrastructure
for data sharing.
-Delays in obtaining inter-institutional data sharing agreements.
-Time lag for distant reference lab results.
-No apparent benefit to those affected to share data.
-Delayed data sharing due to academic competition culture.
Data and sample sharing
-International agencies (e.g. WHO) to establish international data
sharing frameworks.
-Refinement of international agreements, such as the Declaration of
Helsinki to include instructions on how to handle benefit sharing for
sponsor and host countries.
-Develop templates and platforms for data and sample sharing.
-Enhance the value of research output dissemination to all
stakeholders through long-term collaboration and health system
improvements.
-Funding approvals to incorporate agreement on data dissemination.
-Establish data sharing ahead of emergencies.
-Develop a mechanism to manage intellectual property and data
governance.
-Establish standard to reduce uncredited secondary analysis to
facilitate data sharing.
-Ensure global sharing of data with fair distribution.
-Enhance the value of the research to each beneficiary through fair
dissemination of knowledge, product development, long-term re-
search collaboration, and/or health system improvements.
Data and sample sharing
-Data collection and sharing on paper records sometimes not
possible due to infection control and confidentiality issues.
-Loss of control and ownership of data following dissemination.
-Data not made available during outbreaks and long delays in
publishing data after outbreaks.
-Issues around maintaining participant confidentiality when sharing
data.
-Lack of control of communication.
-Confidentiality requirements imposed by commercial entities.
Publication standards
-Agree open data sharing and publication standards.
-A shift in paradigm to a common goal of data sharing rather than
publication.
-Ensure pre-prints of novel data are available prior to publication.
-Develop and use an ‘emergency research pledge’ by journals.
-Ensure researchers, including local collaborators, are credited for
their work.
Traditional publication process
-Traditional journal review processes are too slow to inform
emergency outbreak response strategies.
-Publication authorship imbalances.
Pathways for regulatory and ethics approvals
-Establish accelerated regulatory pathways and expedited ethical
review processes for emergencies.
-Establish institutional review boards in epidemic ‘hot spot’ regions.
-Enable single portals for applications.
-Establish joint ethics review committees.
-Enable parallel submission of ethical, financial and scientific
approvals.
-Develop pre-approved study protocols with agreed acceptable study
design modifications.
-Develop pre-approved site agreements, between multiple sites and
organisations, in geographically strategic regions.
-Consideration of the management of bio-samples should be part of
the ethical and protocol review.
Pathways for regulatory and ethics approvals
-Delays caused by existing ethical frameworks.
-Complex ethic committee forms and inconsistencies between
forms.
-Variation in REB responses to the same study.
-Lack of framework to fast-track vaccine trials or drug testing.
-Existing frameworks not fit for emergency research.
-Lengthy time taken to gain research approvals during epidemics
and pandemics.
-Requirement of approval from multiple entities (including political)
and variations between countries.
-Reluctance from national officials to approve trials.
Drug and vaccine licencing and access
-Form Joint Scientific Advisory and Data Safety Review Committees
for all studies linked to a specific intervention or group of
interventions.
-Global regulatory agencies should collaborate to ensure accelerated
licensure strategy.
-Contracts with multiple manufacturing and distribution units to
improve resilience in the supply of medicines to participating trial
site.
-Primary role of authorising use of investigational vaccines and drugs
should be given to the affected countries.
Drug and vaccine licencing and access
-Length of time for drugs and vaccines to be approved.
-Lack of framework to fast-track vaccine trials and drug testing.
Research support systems
-Provide sufficient funds for the renovation of study facilities and
provide supportive infrastructure.
-Strengthen satellite and wireless internet access in epidemic-prone
regions.
-Use existing infrastructure, e.g. from other disease programmes.
Research support systems
-Rudimentary and overwhelmed healthcare facilities.
-Technical resource limitations.
-Limited access to freezer storage facilities.
-Difficulty reaching remote field sites.
-Lack of effective personal protective equipment
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essential data sharing during emergencies [27, 52, 68]. Jour-
nals were advised to pledge that data sharing during an
emergency would not prejudice later publication [73]. A
shift in perspective to a common goal, rather than publica-
tions, was called for [2, 52, 73]. There were no data on the
implementation of emergency data sharing initiatives
identified.
A publication paradigm must change when lives are
at risk. Shaw et al [73]
Ethical and social solutions identified (Table 4)
The temporal and spatial variation in the risk of infec-
tion during outbreaks presents not only statistical hur-
dles but also an ethical challenge for study designs [75].
Previous research responses have highlighted the many
challenges in agreeing on simultaneously ethical, scien-
tifically valid and acceptable study designs [18, 36, 42,
51, 59, 64, 66], addressing socially valuable questions
[14, 18, 64, 66]. The exclusion of children and pregnant
women was an ethical concern during the Ebola out-
break in LMICs [18, 69], compounded by challenges of
obtaining complex consent [2, 4, 5, 15, 18, 21, 25, 32, 34,
44–46, 50, 69, 70]. Ethical issues also arose around
equity in access to health care for participants and non-
participants [44, 50, 59].
There were calls for international standards for the
conduct of emergency research [21, 51, 60, 62],
Table 4 Solutions to PEARLES challenges encountered (Continued)
-Set up logistical support platforms.
-Ensure flexible solutions that can be readily adaptable depending on
the context.
-Poor safety for staff and participants.
Ethical and social solutions identified Challenges encountered
Standards
-Develop standards for the conduct of research in emergencies,
including frameworks for the inclusion of vulnerable groups and
appropriate study designs.
-Ensure equitable access to best available evidence-based care for all
patients, regardless of consent to participate.
-Ensure appropriate compensation for participation in research.
Standards
-Lack of uniform standards for research ethics committees.
-Lack of international consensus about research groups’ obligations
to provide trial participants health benefits.
-Non-transparent ethical approval processes.
-Exclusion of pregnant women and children from trials.
-Expedited review might pose a risk to patients.
-Research perceived as the only way to access care/treatment.
-Lack of agreement on appropriate study designs for emergencies.
Consent methods
-Evaluate alternative consent methods proposed during emergencies.
-Ensure consent methods are culturally appropriate.
Consent methods
-Obtaining complex informed consent, from severely ill patients
and from relatives.
-Verbal proxy consent contested at later date.
Community engagement
-Invest in community engagement from inception.
-Explore outbreak and community context, and use the findings to
inform the study design, set-up, delivery and dissemination.
-Ensure protocol and consent forms are consistent with community
values and internationally accepted ethical principles.
-Build trust through understanding and respect of different cultures.
-Ensure study design meets cultural needs.
-Manage expectations of all stakeholders.
-Facilitate community empowerment.
-Provide outreach community information sessions.
-Establish community advisory boards.
-Use social messaging and informational materials to improve the
knowledge and perception of the study and disease and to address
rumours.
-Ensure effective consultation and communication with affected or
at-risk communities, for example, through community liaison teams.
-Involve social scientists and medical anthropologists to help
understand the concerns and needs of the community.
-Translate social science research into practice.
-Facilitate relationships between groups with cultural differences.
Community engagement
-Mistrust, suspicion and rumours around clinical trials, national and
international response, sometimes due to local media and other
sources.
-Poor understanding of how to address rumours.
-Fear of the disease.
-Cultural perceptions of tissue and blood sampling.
-Poor understanding of how to respect different cultures.
-Lack of community engagement and poor perception of power
dynamics.
-Perception of research being unfair.
Table 5 Time to initiate an observational study into severe
acute respiratory infections in Canada [15]
Set-up time frames Outbreak Study
setting
Time frame, days,
median (IQR)
Overall start-up procedures H1N1 Canada 335 (128–335)
Site receipt of the protocol
to REB submission
73 (30–126)
REB submission to REB approval 43 (13–85)
Protocol receipt to signed data
sharing agreement
276 (186–312)
REB research ethics board
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including refined definitions of what constitutes research
under these circumstances [51], acceptable study designs
[14] and simplified consent methods [2, 3, 6, 25, 37, 46,
51, 70, 74]. Some studies explored waivered consent [2,
25, 69, 70, 74] and/or proxy consent [69]. However,
gaining proxy consent was also found to be challenging
during emergencies [15]. A qualitative study set in Eur-
ope found public support for consent waiver for publicly
funded, low-risk studies and routinely collected anon-
ymised biological samples for research, and for advanced
or verbal consent models for pandemics [70, 74]. An
interventional Ebola study set in Guinea reported patient
preference for verbal consent [69]. One article
highlighted the risks of using non-documented verbal
consent [5]. Some, but not all countries, allow research
without consent under emergency conditions [2]. Cook
et al. argued that a priori and surrogate consent models
may be contrary to the public good for research involv-
ing critically ill patients during an emerging pandemic
and presented a contextually dependent consent model
[2]. There was a consensus on recommendations for
equitable access to the best available standard of care re-
gardless of consent to participate [29, 32, 50, 59].
Community engagement
The need to engage communities is recognised as essen-
tial for an effective response. Several articles reported
fear and mistrust of international responses as a chal-
lenge for research delivery [18, 51, 69, 71, 79]. Integrat-
ing all stakeholders into each step of the developing
research programme [3, 48, 69], engaging communities
as partners [1, 3] and gaining an understanding of power
dynamics [34] were facilitators cited to address this. It
was also emphasised that interventions need to be cul-
turally sensitive [27, 29, 44, 50, 51, 58] and respond to
national as well as global need [36]. Examples of com-
munity engagement included regular information ses-
sions [3, 5, 16, 29, 34, 42, 69–71], joint communication
plans [20, 29], outreach health promotion teams [69]
and formation of community advisory boards [69].
Discussion
Our findings highlight the many challenges experienced
in the planning, conduct and dissemination of clinical
research responses during epidemic and pandemic
emergencies and the gap in data on our collective cap-
ability to respond globally. Although a range of solutions
to address these challenges were identified, we did not
identify any studies that formally evaluated these during
emergencies. We note the consistency with which key
recommendations for change have been made across dif-
ferent outbreak experiences. Recommendations made to
mitigate challenges experienced during the response to
the H1N1 pandemic in 2009 were not globally imple-
mented, and the same issues were documented again
during the Ebola response in 2014 to 2016. Most chal-
lenges experienced were similar across outbreaks and
settings, with additional challenges due to limited
healthcare systems and infrastructure encountered in
LMICs, and when initiating multi-site responses. The
limited data on our capability to respond to a pandemic
in LMICs is another area of concern. These hard-
learned lessons need firm commitment and action to
build clinical research preparedness for future scenarios
[83]. Challenges to making progress are varied but in-
clude funding shortfalls in the wake of an epidemic as
interest wanes [84], structural problems affecting epi-
demic responses more generally [85] and the absence of
clear accountability for action in a policy area that de-
pends on networked responses from many stakeholders
across disciplinary and institutional boundaries [83].
This review shows a need to strengthen global collabo-
rations and investments to strengthen research capacity
and capability, targeting regions prone to and vulnerable
to epidemics in inter-epidemic times. Progress has been
made in some areas. The UK NIHR portfolio of ‘hiber-
nating’ pre-approved protocols [86], the global research
collaboration for infectious disease preparedness [8] and
the WHO blueprint for R&D into high-threat pathogens
[87] are steps in the right direction. However, the latter
does not include pandemic influenza, and the WHO
public health research agenda for influenza does not
constitute a strategic plan of action [88].
The Platform for European Preparedness Against (Re-)
emerging Epidemics (PREPARE) is an example of a clin-
ical network primed to respond through a suite of active,
syndromic studies across Europe [89]. ALERRT and
Pandora-ID-Net are similar networks strengthening re-
search capacity across Africa [90, 91]. These could serve
as models for similar networks globally. Importantly,
Table 6 Expedited ethical review time frames
Expedited ethical review time frames Outbreak Study setting Time frame
Through an accelerated WHO ethical review process, a sub-committee established specifically
for review of Ebola studies reviewed protocols in 6 days (max. 15 days) on average during the
2014–2016 outbreak. Barriers causing delays were mainly protocol related [18].
Ebola 2014–2016 West Africa 6 days on average
An H1N1 pandemic vaccine cohort study in the UK in 2009 was through expedited review
processes approved by the Oxfordshire Research Ethics Committee within 18 days. Subsequent
substantial amendments were approved within 48 h [53].
H1N1 2009 UK 18 days
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these and similar initiatives need to be evaluated and
sustained to capitalise on existing investments. Strategic
strengthening of local research capability globally will re-
duce reliance on external agencies to deliver research re-
sponses, while ensuring research responses are locally
acceptable, ethical in the context and address local needs
and interest. Local and regional empowerment may also
reduce the risk of unethical studies on vulnerable popu-
lations [5]. Work is also needed to review synergies be-
tween different initiatives and disease programmes to
optimise effectiveness, sustainability and coordination.
Integration of research into outbreak response facilitated
the further assessment of a candidate Ebola vaccine dur-
ing the current outbreak in the Democratic Republic of
the Congo (DRC), aiding the containment of the out-
break, illustrating the importance of clinical research for
outbreak control [92]. A recent RCT of four Ebola treat-
ments in DRC shows that well-planned scientifically and
ethically sound clinical research can be delivered during
prolonged outbreaks, through coordinated collaborative
efforts between a wide range of stakeholders, including
frontline staff and patients [93].
A key strength of this study is that it is the first to
consider the wide range of challenges to the design and
delivery of clinical research during emergency epidemics
from a global perspective. The search strategy was com-
prehensive, spanning multiple databases and incorporat-
ing a range of peer-reviewed literature types.
Nevertheless, due to the paucity of empirical evidence in
this area, we did not carry out a formal quality assess-
ment of included studies. Although findings are limited
by restriction to English language publications, most ar-
ticles addressed challenges to research responses in
LMICs. Most studies were set in West Africa during the
Ebola outbreak or in Europe and Northern America dur-
ing the H1N1 pandemic, highlighting the limited infor-
mation on research preparedness in LMICs and
collective preparedness to deliver timely, coordinated re-
search responses to emergency epidemics globally.
Conclusion
This systematic scoping review shows that potentially ef-
fective measures are not being universally implemented
despite a good degree of expert consensus on their likely
utility. Clinical research communities globally need to
evaluate activities, implement solutions identified during
previous emergency responses and rehearse and refine
outbreak response plans in inter-epidemic times, in col-
laboration with other organisations involved in outbreak
response. Although there may be examples of additional
solutions identified in other regions of the world that were
not included in this review, we have shown that there is
already a substantial body of literature containing valuable
experiences and important recommendations. However,
without concerted, global action to act and to evaluate
those actions in integrated outbreak response plans glo-
bally, we may be destined to encounter the same chal-
lenges and read about the same suggested solutions in the
future. This would mean missed opportunities to forward
knowledge into the clinical management of emerging in-
fectious diseases, improve outcomes and strengthen global
health security.
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